Market Overview

Benzinga's Top #PreMarket Losers

Related TRGT
Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation Coagulation Factor VIIa in Patients With Hemophilia A or B and Preclinical Results
Targacept and Catalyst Biosciences Amend Definitive Merger Agreement
Related RMTI
Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology (ASN) Clinical Meeting November 2015
Oppenheimer's Still Buying Rockwell Medical: Channel Checks And Insider Buying Explain Why
The Biotech Infection - Cramer's Mad Money (10/6/15) (Seeking Alpha)

Targacept (NASDAQ: TRGT) shares fell 31.93% to $4.05 in the pre-market trading after the company announced negative top-line results from Phase 2b clinical trial of TC-5619 in Schizophrenia.

Rockwell Medical (NASDAQ: RMTI) dipped 12.03% to $11.85. Brean Capital initiated coverage on the stock with a Sell rating.

Expedia (NASDAQ: EXPE) dipped 7.47% to $60.96 in the pre-market session. Expedia's trailing-twelve-month profit margin is 3.15%.

Fiserv (NASDAQ: FISV) shares dropped 3.21% to $54.87 in pre-market trading. Fiserv's PEG ratio is 2.67.

Posted-In: PreMarket LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (EXPE + FISV)

Get Benzinga's Newsletters